mirdametinib   Click here for help

GtoPdb Ligand ID: 7935

Synonyms: Gomekli® | PD 0325901 | PD-0325901 | PD0325901
Approved drug PDB Ligand
mirdametinib is an approved drug
Compound class: Synthetic organic
Comment: Mirdametinib (PD 0325901) is a selective and non ATP-competitive MEK inhibitor [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

mirdametinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 90.82
Molecular weight 482
XLogP 3.4
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OCC(CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O
Isomeric SMILES OC[C@H](CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O
InChI InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
InChI Key SUDAHWBOROXANE-SECBINFHSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Mirdametinib (PD 0325901) was progressed to clinical trials for advanced KRAS mutant colorectal cancer (in combination with dacomitinib), KRAS mutant non-small cell lung cancer (in combination with palbociclib) and neurofibromatosis type 1 (NF1). The FDA granted orphan designation for this compound to be used to treat NF1, in October 2018. Development in non-small-cell lung cancer and melanoma, colonic neoplasms and breast cancer was subsequently discontinued. In early 2025, the FDA approved mirdametinib to treat neurofibromatosis type 1 (NF1) with unresectable symptomatic plexiform lesions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02022982 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Phase 1 Interventional Dana-Farber Cancer Institute
NCT02039336 Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC Phase 1/Phase 2 Interventional The Netherlands Cancer Institute
NCT02096471 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Phase 2 Interventional University of Alabama at Birmingham 3